Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 10/20 | 0.39 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM4B | O94953 | 2/20 | 0.38 |
| ▸ | KDM5C | P41229 | 2/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4332652 | 0.88 | GAA (0.41) | TBXAS1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL4337828 | 0.85 | TBXAS1 (0.41) | TBXAS1PDK2GPR35 | |
| SCHEMBL4333890 | 0.84 | KDM4E (0.41) | — | |
| SCHEMBL4325427 | 0.83 | ACVR1 (0.36) | KDM4AKDM4BKDM5CKDM5BPDK2 | |
| SCHEMBL4337751 | 0.76 | BRD4 (0.41) | TBXAS1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL4339090 | 0.74 | BACE1 (0.42) | PARP1 | |
| SCHEMBL4330570 | 0.70 | KDM4E (0.42) | — | |
| SCHEMBL4337689 | 0.69 | ACVR1 (0.38) | PDK2 | |
| SCHEMBL4341331 | 0.67 | HPGDS (0.43) | KDM4AKDM4BKDM5CKDM5BGABRA1 | |
| SCHEMBL4558204 | 0.67 | PARP1 (0.34) | KDM4AKDM4BKDM5CKDM5BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661897-B1 | PYRROLOPYRIMIDINONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1661897-A1 | PYRROLOPYRIMIDINONE DERIVATIVE | Teijin Pharma Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | GSK3B, GSK3A, GSKIP | TBXAS1 2476/4885KDM4A 915/4885KDM4B 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.